Eliksa Therapeutics is a venture-backed biotechnology company with a proprietary cGMP production facility and a robust clinical pipeline addressing unmet medical needs in ocular and cardiovascular indications. Our lead candidate, ELK-003, is a novel multi-target biological modulating inflammation, cell recovery, and tissue healing. ELK-003 has proven to be safe and well-tolerated with 18,000+ human doses without any reported side effects.

Biotechnology

Health Care

Eliksa Therapeutics

Eliksa Therapeutics' headquarters in Doylestown, PA, United States

Description

People (2)

Armen Karamanian, MD, PhD

Jane Hollingsworth

Jobs